Molecular characterization as a target for cancer therapy in relation to orphan status disorders (Review)

Oncology Reports

Volumn 9, Issue 6, 2002, Pages 1257-1259

  Stathopoulos, G P ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Target cancer treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; ENZYME INHIBITOR; FOLIC ACID ANTAGONIST; IMATINIB; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; HUMAN; NEOPLASM; PHYSIOLOGY; PROTO ONCOGENE; REVIEW;

ANTINEOPLASTIC AGENTS; CANCER VACCINES; ENZYME INHIBITORS; FOLIC ACID ANTAGONISTS; GENES, ERBB-1; HUMANS; NEOPLASMS; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 0036834244     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.9.6.1257     Document Type: Review

References (20)

1. Wyllie AH: Apoptosis and cancer chemotherapy. Hickmans IA and Dive C (eds). V-VII. Humana Press, Totowa, New Jersey, 1999.
2. Sausville EA: Scientific Symposium: early clinical trials of new therapeutic and preventive agents. Educational Book. Am Soc Clin Oncol, pp64-67, 2000.
3. Warnell RP Jr, Frankel SR, Miller WH Jr, et al: Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 324: 1385-1393, 1991.
4. Pegram MD, Lipton A, Hayes DF, et al: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-P 185 HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16: 2659-2671, 1998. (Pubitemid 28363029)
5. Cooley S, Burns LJ, Repka T and Miller JS: Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol 27: 1533-1538, 1999.
6. Baselga J, Norton L, Albanell J, et al: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58: 2825-2831, 1998. (Pubitemid 28311914)
7. Levitzki A and Gazit A: Tyrosine kinase inhibition: an approach to drug development. Science 267: 1782-1788, 1995.
8. Sawyers CL: Chronic myeloid leukemia. N Engl J Med 340: 1330-1340, 1999.
9. Faderi S, Talpaz M, Estrov Z, et al: The biology of chronic myeloid leukemia. N Engl J Med 341: 164-172, 1999. (Pubitemid 29325745)
10. Talpaz M, Estrov Z, Kantarjian H, et al: Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. J Clin Invest 94: 1383-1389, 1994.
11. Druker BJ, Talpaz M, Resta D, et al: Clinical efficacy and safety of an ABL-specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia. Blood 94: 1639, 1999.
12. Mendelson J: Epidermal growth factor receptor blockade as anticancer therapy. Educational Book. Am Soc Clin Oncol pp39-41, 2001.
13. KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 12: 1397-1403, 1996.
14. Huang SM and Harari PM: Modulation of radiation response following epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics and tumor angiogenesis. Clin Cancer Res 6: 2166-2174, 2000.
15. Huang SM, Bock JM and Harari PM: Epidermal growth factor receptor blockade with C225 modulates proliferation apoptosis and radiosensitivity in squamous cell carcinoma of the head and neck. Cancer Res 59: 1935-1940, 1999. (Pubitemid 29186168)
16. Bianco C, Bianco R, Tortora G, et al: Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody 225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res 6: 4343-4350, 2000.
17. Beutler E: Cladribine (2 chlorodeoxy adenosine). Lancet 340: 952-956, 1992.
18. Armitage JO: Treatment of non-Hodgkin's lymphoma. N Engl J Med 328: 1023-1030, 1993.
19. Calvert AH, Hughes AN, Calvert PM, et al: MTA (LY231514) demonstrate clinical activity against malignant mesothelioma in a phase I combination trial with carboplatin. Eur J Cancer 35 (Suppl. 4): 285-286, 1999.
20. Rosenberg SA: Development of cancer vaccines. Educational Book. Am Soc Clin Oncol, pp60-62, 2000.